Merck Surges After-Hours on Q1 Earnings Beat and Raised Outlook as Keytruda Dominance Continues

Core Growth Drivers Overcome Acquisition Noise

Merck & Co. (MRK) emerged as a standout performer in extended trading on Thursday, with its 2.69% gain coming on heavy volume of 16.8 million shares. The move represents a significant divergence from the broader market, as the S&P 500 (SPY) remained unchanged after the close. The primary catalyst was a first-quarter earnings report that demonstrated the underlying strength of Merck's product pipeline, even as the company navigated complex business development charges.

For the first quarter of 2026, Merck reported worldwide sales of $16.3 billion, a 5% increase year-over-year that surpassed the consensus estimate of $15.91 billion. While the company posted a non-GAAP loss of $1.28 per share, this figure was better than the $1.31 to $1.48 loss analysts had feared. The loss was entirely attributed to a $9 billion, or $3.62 per share, one-time charge related to the acquisition of Cidara Therapeutics. Excluding these one-time items, the company's operational performance remained exceptionally strong.

Keytruda and Winrevair Lead the Charge

The rally in after-hours trading was fueled by the continued dominance of Keytruda, the world's top-selling cancer drug. Keytruda sales reached $8.0 billion for the quarter, a 12% increase. Critically, the new subcutaneous version, Keytruda QLEX, contributed $128 million in its first full quarter following a permanent J-code assignment, signaling a successful lifecycle management strategy ahead of the drug's 2028 patent cliff.

Even more impressive to analysts was the performance of Winrevair, Merck's new treatment for pulmonary arterial hypertension. Winrevair sales surged 88% to $525 million, crushing expectations and proving that Merck is successfully diversifying its revenue streams beyond oncology. CEO Robert M. Davis noted that the company is "moving with speed to transform our portfolio" into one with multiple growth engines across therapeutic areas.

Guidance Hike and Strategic Acquisitions

Adding to the positive sentiment in the after-hours session, Merck raised its full-year 2026 financial outlook. The company now expects total sales to fall between $65.8 billion and $67.0 billion, up from its previous floor of $65.5 billion. It also tightened and raised the midpoint of its non-GAAP EPS guidance to a range of $5.04 to $5.16.

Investors also reacted to Merck's announcement of a new agreement to acquire Terns Pharmaceuticals for approximately $6.7 billion. This deal, expected to close in May, aims to bolster Merck's hematology pipeline with TERN-701, a promising candidate for chronic myeloid leukemia. While this will result in another one-time charge of roughly $2.35 per share later this year, the market appears to be rewarding Merck's aggressive pursuit of high-value clinical assets to secure long-term growth.

Forward-Looking Perspective

Looking ahead, Merck is entering what management describes as a "robust period" of Phase 3 data readouts. With Keytruda's subcutaneous transition gaining traction and Winrevair's launch exceeding even bullish projections, the company has effectively silenced critics concerned about its upcoming patent expirations. While legacy products like the diabetes drug Januvia and the HPV vaccine Gardasil saw sales declines this quarter, the overwhelming strength of the new growth portfolio suggests Merck is well-positioned to maintain its leadership in the pharmaceutical sector through 2026 and beyond.